

## Pteridinecarboxamide Diuretics. II. Reaction of 4,6-Diamino-5-nitrosopyrimidines with N-Substituted Cyanoacetamides<sup>1</sup>

T. S. OSDENE, ARTHUR A. SANTILLI,<sup>2</sup> LEE E. MCCARDLE, AND MARVIN E. ROSENTHALE

Wyeth Laboratories, Inc., Research and Development Division, Radnor, Pennsylvania

Received September 24, 1966

Several new 4,6-diamino-2-substituted 5-nitrosopyrimidines and N-substituted 2-cyanoacetamides were prepared and used as intermediates in the base-catalyzed preparation of a number of 4,7-diamino-2-substituted N-substituted 6-pteridinecarboxamides. Many of these pteridines were examined for diuretic activity in rats after oral administration. Increased activity was associated with certain specific structural characteristics. The more active compounds were those in which the 2 position of the pteridine nucleus bears an aromatic group, preferably phenyl or *m*-chlorophenyl, and in which the carbamoyl nitrogen bears a 2-dialkylaminoethyl or 2-(N-heterocyclic amino)ethyl group, e.g., 2-diethylaminoethyl or 2-morpholinoethyl.

In the preceding paper of this series<sup>3</sup> the structure-diuretic activity relationship of 4-amino-2-substituted 7-substituted amino-N-substituted 6-pteridinecarboxamides prepared from 4,6-diamino-2-substituted 5-nitrosopyrimidines and N,N'-bis-substituted malonamides was discussed. In the present work a number of new 4,7-diamino-2-substituted N-substituted 6-pteridinecarboxamides were prepared by the reaction of 4,6-diamino-2-substituted 5-nitrosopyrimidines with N-substituted 2-cyanoacetamides (see Chart I and


(Table III) were prepared by previously described procedures.<sup>5</sup> Reaction of the latter compounds with N-substituted cyanoacetamides in refluxing ethanol containing catalytic amounts of sodium afforded the pteridinecarboxamides (Tables IV-V) used in this study. In those pteridines prepared from 4,6-diamino-5-nitrosopyrimidines bearing a 2-amino function, it was necessary to use a higher boiling solvent for reaction to occur. 2-Ethoxyethanol was found to be suitable for this purpose.

An examination of the infrared spectra of the pteridines thus prepared revealed the expected carbonyl and amino absorption bands. A typical example is given below.

**Biological Methods.**—The procedure used for evaluating the diuretic profiles of the pteridinecarboxamides in male Sprague-Dawley rats has been previously described in detail.<sup>3</sup> The results in Tables VI-X are expressed as the average ratios of urine volume and sodium levels in test (T) animals to those of the control urea-dosed (U) animals. All ratios (T/U) greater than unity for volume and sodium output represent statistically significant diuretic responses. This preliminary screening procedure was quite useful in that it afforded a means of rapidly evaluating the action of each drug on a quantitative basis. Further biological evaluation of the more active compounds has been carried out and is typified by other reports cited below.

**Structure-Activity Relationships.**—Table VI gives the relative diuretic response of a number of 4,7-diamino-2-phenyl-6-pteridinecarboxamides having various substituents (R<sub>2</sub>) bonded to the N atom of the 6-carbamoyl group. In general, the more active pteridines are those in which R<sub>2</sub> contains an amino group, e.g., **96**, **103**, **109**, **116**, and **118**. The most active of these are **103** and **118** where R<sub>2</sub> = 2-diethylaminoethyl and 2-morpholinoethyl, respectively. A more detailed account of the diuretic action of **118** in rats and dogs has recently been given.<sup>6</sup> The action of this drug has been compared with several other diuretic agents.<sup>7</sup>

Table VII shows the results of retaining an active moiety such as the 2-diethylaminoethyl group on the carbamoyl nitrogen but varying the substituent in the



Tables I-V). The first descriptions of this type of synthesis were reported several years ago.<sup>4</sup> Many of the 6-pteridinecarboxamides given herein were found to be active diuretics when tested orally in rats. These compounds differ from those presented in the previous paper by having substituted in the 7 position of the pteridine nucleus an amino group rather than a hydroxy or substituted amino group. Slight modifications in structure at the 2 and 6 positions resulted in significant changes in activity and a systematic study was undertaken to determine the relationship between these structural changes and diuretic profile. Certain generalities have been observed and are presented in this report.

**Chemistry.**—The method used for the earlier syntheses of 4,7-diamino-6-pteridinecarboxamides<sup>4</sup> has now been expanded to include the preparation of 4,7-diamino-N-substituted 6-pteridinecarboxamides. The N-substituted cyanoacetamides required as intermediates were prepared generally by heating ethyl cyanoacetate with 1 equiv of a primary amine (Table I) or secondary amine (Table II) in refluxing ethanol. Various 4,6-diamino-2-substituted 5-nitrosopyrimidines

(1) This work was presented in part before the Division of Medicinal Chemistry, 150th National Meeting of the American Chemical Society, Atlantic City, N. J., Sept 1965, p 16 P.

(2) To whom inquiries should be addressed.

(3) T. S. Osdene, A. A. Santilli, L. E. McCardle, and M. E. Rosenthale, *J. Med. Chem.*, **9**, 697 (1966).

(4) (a) T. S. Osdene and G. M. Timmis, *Chem. Ind. (London)*, 405 (1954);


(b) T. S. Osdene and G. M. Timmis, *J. Chem. Soc.*, 2036 (1955).

(5) O. Vogl and E. C. Taylor, *J. Am. Chem. Soc.*, **79**, 1518 (1957); E. C. Taylor, O. Vogl, and C. C. Cheng, *ibid.*, **81**, 2442 (1959), and other sources given in ref 3.

(6) M. E. Rosenthale and C. G. Van Arman, *J. Pharmacol. Exptl. Therap.*, **142**, 111 (1963).

(7) M. E. Rosenthale, *ibid.*, **147**, 399 (1965).

TABLE I  
 N-SUBSTITUTED 2-CYANOACETAMIDES  
 NCCH<sub>2</sub>CONHR<sub>2</sub>

| Compd | R <sub>2</sub>  | Mp or<br>bp. (mm), °C | Recrystn<br>solvent <sup>a</sup> | Yield,<br>% | Formula   | C     | H     | N     | Calcd <sup>b</sup><br>C | Calcd <sup>b</sup><br>H | Calcd <sup>b</sup><br>N | Found <sup>c</sup><br>C | Found <sup>c</sup><br>H | Found <sup>c</sup><br>N |
|-------|---|-----------------------|----------------------------------|-------------|---|-------|-------|-------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| 1     | CH <sub>3</sub> <sup>a</sup>  | 100                   | A                                | 60          |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 2     | C <sub>2</sub> H <sub>5</sub> <sup>a</sup>  | 73                    | A                                | 94          |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 3     | <i>o</i> -C <sub>6</sub> H <sub>5</sub>   | 104                   | A                                | 59          | C <sub>6</sub> H <sub>5</sub> N <sub>2</sub> O                | 58.05 | 6.50  | 22.57 | 57.94                   | 6.40                    | 22.36                   |                         |                         |                         |
| 4     | <i>c</i> -C <sub>6</sub> H <sub>5</sub>   | 87                    | J-F                              | 64          | C <sub>8</sub> H <sub>12</sub> N <sub>2</sub> O               | 63.13 | 7.95  | 18.41 | 62.97                   | 8.10                    | 18.36                   |                         |                         |                         |
| 5     | <i>c</i> -C <sub>6</sub> H <sub>11</sub> <sup>d</sup>   | 132                   | A-C                              | 36          | C <sub>9</sub> H <sub>14</sub> N <sub>2</sub> O               | 65.03 | 8.49  | 16.85 | 64.72                   | 8.47                    | 16.90                   |                         |                         |                         |
| 6     | <i>c</i> -C <sub>7</sub> H <sub>13</sub>  | 94                    | A-D                              | 58          | C <sub>10</sub> H <sub>16</sub> N <sub>2</sub> O              | 66.63 | 8.95  | 15.54 | 66.69                   | 9.21                    | 15.68                   |                         |                         |                         |
| 7     | <i>c</i> -C <sub>8</sub> H <sub>15</sub>  | 74                    | A-D                              | 51          | C <sub>11</sub> H <sub>18</sub> N <sub>2</sub> O              | 68.00 | 9.34  | 14.42 | 68.10                   | 9.20                    | 14.67                   |                         |                         |                         |
| 8     | (CH <sub>2</sub> ) <sub>2</sub> OH <sup>e</sup>   | 61                    | B                                | 65          |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 9     | CHC <sub>2</sub> H <sub>5</sub> CH <sub>2</sub> OH <sup>f</sup>   | 87                    | B-C                              | 92          |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 10    | CGH <sub>3</sub> (CH <sub>2</sub> OH) <sub>2</sub> <sup>f</sup>   | 131                   | A-B                              | 74          |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 11    | (CH <sub>2</sub> ) <sub>2</sub> O(CH <sub>2</sub> ) <sub>2</sub> OH <sup>g</sup>                              |                       |                                  |             |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 12    | (CH <sub>2</sub> ) <sub>2</sub> OCH <sub>3</sub>  | 79                    | B                                | 53          | C <sub>6</sub> H <sub>10</sub> N <sub>2</sub> O <sub>2</sub>  | 59.69 | 7.09  | 19.71 | 59.71                   | 7.02                    | 19.86                   |                         |                         |                         |
| 13    | (CH <sub>2</sub> ) <sub>3</sub> OCH <sub>3</sub>  | 61                    | B                                | 55          | C <sub>7</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub>  | 53.83 | 7.74  | 17.94 | 53.62                   | 7.65                    | 17.83                   |                         |                         |                         |
| 14    | (CH <sub>2</sub> ) <sub>2</sub> OC <sub>2</sub> H <sub>5</sub>  | 45                    | A-C                              | 52          | C <sub>7</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub>  | 53.83 | 7.74  | 17.94 | 53.70                   | 7.73                    | 17.82                   |                         |                         |                         |
| 15    | (CH <sub>2</sub> ) <sub>3</sub> OC <sub>2</sub> H <sub>5</sub>  | 55                    | B-C                              | 76          | C <sub>8</sub> H <sub>14</sub> N <sub>2</sub> O <sub>2</sub>  | 56.45 | 8.29  | 16.46 | 56.28                   | 8.31                    | 16.17                   |                         |                         |                         |
| 16    | CH <sub>2</sub> CH(OC <sub>2</sub> H <sub>5</sub> ) <sub>2</sub>  | 52                    | A-J                              | 52          | C <sub>9</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub>  | 53.98 | 8.06  | 13.99 | 53.74                   | 7.98                    | 14.30                   |                         |                         |                         |
| 17    | (CH <sub>2</sub> ) <sub>3</sub> OCH(CH <sub>3</sub> ) <sub>2</sub> <sup>g</sup>                               | 38                    |                                  | 64          | C <sub>9</sub> H <sub>16</sub> N <sub>2</sub> O <sub>2</sub>  | 58.67 | 8.75  | 15.21 | 58.64                   | 9.07                    | 15.28                   |                         |                         |                         |
| 18    |                              | 55                    |                                  | 80          |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 19    | (CH <sub>2</sub> ) <sub>2</sub> SC <sub>2</sub> H <sub>5</sub> <sup>a</sup>                                   | 52                    | K                                | 35          | C <sub>7</sub> H <sub>12</sub> N <sub>2</sub> OS              | 48.81 | 7.02  | 16.26 | 49.10                   | 7.11                    | 16.04                   |                         |                         |                         |
| 20    | CH <sub>2</sub> CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> <sup>f</sup>                                    | 99                    | J                                | 36          |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 21    | <i>p</i> -C <sub>6</sub> H <sub>5</sub> OCOC <sub>6</sub> H <sub>4</sub>                                      | 94                    | D                                |             | C <sub>12</sub> H <sub>12</sub> N <sub>2</sub> O <sub>3</sub> | 62.06 | 5.21  | 12.06 | 62.30                   | 5.64                    | 11.99                   |                         |                         |                         |
| 22    | (CH <sub>2</sub> ) <sub>2</sub> NH <sub>2</sub> ·maleate  | 96                    | A                                |             | C <sub>9</sub> H <sub>13</sub> N <sub>3</sub> O <sub>3</sub>  | 44.44 | 5.39  | 17.28 | 44.41                   | 5.16                    | 17.20                   |                         |                         |                         |
| 23    | (CH <sub>2</sub> ) <sub>3</sub> NHC <sub>6</sub> H <sub>11</sub> <sup>e-g</sup>                               | 75                    |                                  | 36          |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 24    | (CH <sub>2</sub> ) <sub>2</sub> N(CH <sub>3</sub> ) <sub>2</sub>  | 147 (1.0)             |                                  | 66          | C <sub>7</sub> H <sub>13</sub> N <sub>3</sub> O               | 54.17 | 8.44  | 27.08 | 54.21                   | 8.73                    | 26.00                   |                         |                         |                         |
| 25    | (CH <sub>2</sub> ) <sub>3</sub> N(CH <sub>3</sub> ) <sub>2</sub>  | 128-129 (0.5)         |                                  | 71          | C <sub>8</sub> H <sub>15</sub> N <sub>3</sub> O               | 56.78 | 8.94  | 24.83 | 55.84                   | 8.65                    | 24.45                   |                         |                         |                         |
| 26    | (CH <sub>2</sub> ) <sub>4</sub> N(CH <sub>3</sub> ) <sub>2</sub>  | 148-149 (0.35)        |                                  | 59          | C <sub>9</sub> H <sub>17</sub> N <sub>3</sub> O               | 58.98 | 9.35  | 22.93 | 59.28                   | 9.54                    | 22.33                   |                         |                         |                         |
| 27    | (CH <sub>2</sub> ) <sub>5</sub> N(CH <sub>3</sub> ) <sub>2</sub>  | 162-164 (0.3)         |                                  | 46          | C <sub>10</sub> H <sub>19</sub> N <sub>3</sub> O              | 60.88 | 9.71  | 21.30 | 60.72                   | 10.13                   | 21.22                   |                         |                         |                         |
| 28    | (CH <sub>2</sub> ) <sub>6</sub> N(CH <sub>3</sub> ) <sub>2</sub> <sup>h</sup>                                 |                       |                                  |             |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 29    | (CH <sub>2</sub> ) <sub>2</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub>                                | 132 (0.3)             |                                  | 66          | C <sub>9</sub> H <sub>17</sub> N <sub>3</sub> O               | 58.98 | 9.35  | 22.93 | 58.87                   | 9.39                    | 22.79                   |                         |                         |                         |
| 30    | (CH <sub>2</sub> ) <sub>3</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub>                                | 142-143 (0.5)         |                                  | 59          | C <sub>10</sub> H <sub>19</sub> N <sub>3</sub> O              | 60.88 | 9.71  | 21.30 | 60.94                   | 9.87                    | 21.22                   |                         |                         |                         |
| 31    | (CH <sub>2</sub> ) <sub>4</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub>                                | 155-165 (0.4)         |                                  | 46          | C <sub>11</sub> H <sub>21</sub> N <sub>3</sub> O              | 62.52 | 10.02 | 19.89 | 62.70                   | 10.34                   | 19.47                   |                         |                         |                         |
| 32    | (CH <sub>2</sub> ) <sub>5</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> <sup>g</sup>                   |                       |                                  |             |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 33    | (CH <sub>2</sub> ) <sub>7</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> <sup>g</sup>                   |                       |                                  |             |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 34    | (CH <sub>2</sub> ) <sub>2</sub> N( <i>i</i> -C <sub>3</sub> H <sub>7</sub> ) <sub>2</sub>                     | 150 (1.7)             |                                  | 87          | C <sub>11</sub> H <sub>21</sub> N <sub>3</sub> O              | 62.52 | 10.02 | 19.89 | 62.26                   | 10.00                   | 19.75                   |                         |                         |                         |
| 35    | (CH <sub>2</sub> ) <sub>3</sub> N( <i>n</i> -C <sub>4</sub> H <sub>9</sub> ) <sub>2</sub>                     | 184 (1.0)             |                                  | 68          | C <sub>14</sub> H <sub>27</sub> N <sub>3</sub> O              | 66.36 | 10.74 | 16.59 | 65.74                   | 10.35                   | 16.68                   |                         |                         |                         |
| 36    | (CH <sub>2</sub> ) <sub>2</sub> N(CH <sub>2</sub> CH <sub>2</sub> OH) <sub>2</sub> <sup>g</sup>               |                       |                                  |             |   |       |       |       |                         |                         |                         |                         |                         |                         |
| 37    | CH <sub>2</sub> CHCH <sub>3</sub> N(CH <sub>3</sub> ) <sub>2</sub>  | 138 (1.1)             |                                  | 67          | C <sub>8</sub> H <sub>15</sub> N <sub>3</sub> O               | 56.78 | 8.94  | 24.83 | 56.67                   | 8.81                    | 24.32                   |                         |                         |                         |
| 38    | GHCH <sub>3</sub> (CH <sub>2</sub> ) <sub>3</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> <sup>f</sup> | 156-162 (0.3)         |                                  | 47          | C <sub>12</sub> H <sub>23</sub> N <sub>3</sub> O              | 63.96 | 10.29 | 18.65 | 63.91                   | 10.60                   | 18.62                   |                         |                         |                         |
| 39    | 2- <i>l</i> -Pyrrolidinyl)ethyl   | 109                   |                                  | 72          | C <sub>9</sub> H <sub>15</sub> N <sub>3</sub> O               | 59.64 | 8.34  | 23.19 | 59.40                   | 8.36                    | 22.97                   |                         |                         |                         |
| 40    | 2-Piperidinoethyl   | 72                    | B                                | 95          | C <sub>10</sub> H <sub>17</sub> N <sub>3</sub> O              | 61.51 | 8.78  | 21.52 | 61.80                   | 8.97                    | 21.49                   |                         |                         |                         |
| 41    | 3-Piperidinopropyl  | 48                    | B-C                              | 53          | C <sub>11</sub> H <sub>19</sub> N <sub>3</sub> O              | 63.21 | 9.15  | 20.08 | 63.26                   | 8.92                    | 20.10                   |                         |                         |                         |
| 42    | 2-Morpholinoethyl   | 85                    | B                                | 40          | C <sub>9</sub> H <sub>15</sub> N <sub>3</sub> O <sub>2</sub>  | 54.80 | 7.67  | 21.31 | 55.05                   | 7.83                    | 21.27                   |                         |                         |                         |
| 43    | 3-Morpholinopropyl  | 65                    | B                                | 44          | C <sub>10</sub> H <sub>17</sub> N <sub>3</sub> O <sub>2</sub> | 56.85 | 8.11  | 19.89 | 56.89                   | 8.06                    | 19.60                   |                         |                         |                         |
| 44    | 4-Pyridylmethyl   | 116                   | L                                | 26          | C <sub>9</sub> H <sub>9</sub> N <sub>3</sub> O                | 61.70 | 5.18  | 23.99 | 61.74                   | 5.11                    | 24.04                   |                         |                         |                         |

<sup>a</sup> A = ethanol, B = ethyl acetate, C = petroleum ether (bp 30-60°), D = H<sub>2</sub>O, E = 2-ethoxyethanol, F = C<sub>6</sub>H<sub>6</sub>, G = DMF, H = methanol, I = 1-butanol, J = cyclohexane, K = ether, L = acetone, M = acetic acid. <sup>b</sup> K. G. Naik and Y. N. Bhat, *Quart. J. Indian Chem. Soc.*, **4**, 547 (1927); *Chem. Abstr.*, **22**, 2353 (1928), reported mp 101°. <sup>c</sup> Li<sup>h</sup> mp 74°. <sup>d</sup> C. Whitehead and J. Traverso, *J. Am. Chem. Soc.*, **77**, 5867 (1955), reported mp 132°. <sup>e</sup> O. K. Behrens, J. Corse, D. E. Huff, R. G. Jones, Q. F. Soper, and G. W. Whitehead, *J. Biol. Chem.*, **175**, 771 (1948); no melting point reported. <sup>f</sup> Previously reported by A. A. Santilli and T. S. Osden, *J. Org. Chem.*, **29**, 2066 (1964). <sup>g</sup> Sample used without purification. <sup>h</sup> 2-Ethylmercaptoethylamine used in the preparation of **19**, was prepared from ethylenimine and ethyl mercaptan as described by T. Wieland, E. F. Moller, and G. Dieckmann, *Ber.*, **85**, 1035 (1952). <sup>i</sup> O. Diels and H. Heibizel, *ibid.*, **38**, 304 (1905), reported mp 100-101°. <sup>j</sup> C. C. Price and V. Boekelheide, *J. Am. Chem. Soc.*, **68**, 1246 (1946), reported bp 165-170° (2 mm).

2 position of the pteridine nucleus. The only active member of this series is **103** (R<sub>1</sub> = phenyl). The other compounds were inactive at the dose levels shown.

In Table VIII are given compounds in which the same active group is retained on the carbamoyl nitrogen but the substituent R' on the 2-phenyl group is varied. The most active compounds in this series are **103** and **155** in which R' = H and *m*-Cl, respectively. Substitution generally diminished the activity. Compounds **145**, **148**, and **165** were inactive.

Table IX demonstrates the effect of homologation on diuretic response within an active series. The optimal methylene chain length attached to the carbamoyl nitrogen appears to be two (**103**). Activity decreased with a third methylene group (**104**) and was nonexistent for compounds containing four (**105**) or five (**106**) methylene groups in the alkyl chain. Similar results were observed with higher homologs (*n* > 2) in other active pteridines.


Table X shows the diuretic effect in 4,7-diamino-2-phenyl-6-pteridinecarboxamides which have the car-

TABLE II  
2-CYANOACETYLAMINES AND N,N-DISUBSTITUTED 2-CYANOACETAMIDES  
NCCH<sub>2</sub>COR<sub>3</sub>

| Compd | R <sub>3</sub>  | Mp or<br>bp (mm),<br>°C | Recrystn<br>solvent <sup>a</sup> | Yield,<br>% | Formula  | % calcd |       |       | % found |       |       |
|-------|---|-------------------------|----------------------------------|-------------|--|---------|-------|-------|---------|-------|-------|
|       |   |                         |                                  |             |  | C       | H     | N     | C       | H     | N     |
| 45    | 1-Pyrrolidiny1  | 71                      | B                                | 67          | C <sub>7</sub> H <sub>10</sub> N <sub>2</sub> O              | 60.85   | 7.30  | 20.28 | 60.91   | 7.26  | 20.09 |
| 46    | Piperidino <sup>b</sup>   | 87                      | B                                | 76          |  |         |       |       |         |       |       |
| 47    | 1-Hexahydroazepiny1   | 74                      | A-J                              | 73          | C <sub>9</sub> H <sub>14</sub> N <sub>2</sub> O              | 65.03   | 8.49  | 16.85 | 65.19   | 8.60  | 17.10 |
| 48    | Morpholino <sup>b</sup>   | 82                      | F-C                              | 27          |  |         |       |       |         |       |       |
| 49    | Thiomorpholino  | 95                      | D                                | 70          | C <sub>7</sub> H <sub>10</sub> N <sub>2</sub> OS             | 49.39   | 5.92  | 16.46 | 49.72   | 5.93  | 16.74 |
| 50    | 4-Methyl-1-piperaziny1  | 113                     | J                                | 40          | C <sub>8</sub> H <sub>13</sub> N <sub>3</sub> O              | 57.46   | 7.84  | 25.13 | 57.59   | 8.08  | 24.96 |
| 51    | 4-(2-Hydroxyethyl)-1-piper-<br>aziny1   | 84                      | F                                | 83          | C <sub>9</sub> H <sub>15</sub> N <sub>3</sub> O <sub>2</sub> | 54.80   | 7.67  | 21.31 | 55.09   | 7.51  | 21.41 |
| 52    | N(CH <sub>3</sub> ) <sub>2</sub> <sup>c</sup>   | 64                      | B                                | 92          |  |         |       |       |         |       |       |
| 53    | NCH <sub>3</sub> (CH <sub>2</sub> ) <sub>2</sub> N(CH <sub>3</sub> ) <sub>2</sub>   | 147 (0.7)               |                                  | 66          | C <sub>8</sub> H <sub>15</sub> N <sub>3</sub> O              | 56.78   | 8.94  | 24.83 | 56.44   | 8.99  | 24.71 |
| 54    | NCH <sub>3</sub> C <sub>6</sub> H <sub>11</sub> - <i>c</i>  | 82                      | A-D                              | 99          | C <sub>10</sub> H <sub>16</sub> N <sub>2</sub> O             | 66.63   | 8.95  | 15.54 | 67.09   | 8.66  | 15.37 |
| 55    | NCH <sub>3</sub> (CH <sub>2</sub> ) <sub>2</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> <sup>d</sup>                          |                         |                                  |             |  |         |       |       |         |       |       |
| 56    | NC <sub>2</sub> H <sub>5</sub> (CH <sub>2</sub> ) <sub>2</sub> N(CH <sub>3</sub> ) <sub>2</sub>                                       | 147-150<br>(0.7)        |                                  | 21          | C <sub>9</sub> H <sub>17</sub> N <sub>3</sub> O              | 58.99   | 9.35  | 22.93 | 58.65   | 9.15  | 23.14 |
| 57    | NC <sub>2</sub> H <sub>5</sub> (CH <sub>2</sub> ) <sub>2</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> <sup>d</sup>            |                         |                                  |             |  |         |       |       |         |       |       |
| 58    | N( <i>i</i> -C <sub>3</sub> H <sub>7</sub> )(CH <sub>2</sub> ) <sub>2</sub> N( <i>i</i> -C <sub>3</sub> H <sub>7</sub> ) <sub>2</sub> | 86                      |                                  | 79          | C <sub>14</sub> H <sub>27</sub> N <sub>3</sub> O             | 66.36   | 10.74 | 16.59 | 66.28   | 10.63 | 16.36 |

<sup>a</sup> See footnote a of Table I. <sup>b</sup> C. W. Whitehead and J. J. Traverso, *J. Am. Chem. Soc.*, **77**, 5867 (1955), reported mp 87° for both **46** and **48**. <sup>c</sup> E. L. Eliel, *ibid.*, **73**, 43 (1951), reported mp 65-66°. <sup>d</sup> Compound used without purification.

TABLE III  
4,6-DIAMINO-5-NITROSO-2-(SUBSTITUTED) PYRIMIDINES



| Compd | R <sub>1</sub> <sup>a</sup>   | Mp, °C  | Recrystn<br>solvent <sup>b</sup> | Method <sup>c</sup> | Formula   | % calcd |      |       | % found |      |       |
|-------|---|---------|----------------------------------|---------------------|---|---------|------|-------|---------|------|-------|
|       |   |         |                                  |                     |   | C       | H    | N     | C       | H    | N     |
| 59    | CF <sub>3</sub>   | >360    | M-D                              | I                   | C <sub>5</sub> H <sub>4</sub> F <sub>3</sub> N <sub>5</sub> O   | 29.01   | 1.95 |       | 28.55   | 2.16 |       |
| 60    | Morpholino <sup>d</sup>   | 236 dec | A                                | II                  | C <sub>8</sub> H <sub>12</sub> N <sub>6</sub> O <sub>2</sub>    | 42.85   | 5.39 | 37.48 | 43.03   | 5.41 | 37.20 |
| 61    | <i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | 219 dec | A                                | I                   | C <sub>11</sub> H <sub>11</sub> N <sub>6</sub> O <sub>2</sub>   | 57.63   | 4.84 | 30.54 | 57.87   | 5.00 | 31.44 |
| 62    | <i>m</i> -CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub> <sup>a</sup>    | 211     | H                                | I                   | C <sub>11</sub> H <sub>8</sub> F <sub>3</sub> N <sub>6</sub> O  | 46.81   | 2.50 | 24.82 | 46.90   | 2.78 | 24.55 |
| 63    | 3,4-Cl <sub>2</sub> C <sub>6</sub> H <sub>3</sub>                       | 279 dec | E                                | I                   | C <sub>10</sub> H <sub>7</sub> Cl <sub>2</sub> N <sub>6</sub> O | 42.29   | 2.49 | 24.65 | 42.53   | 4.75 | 24.40 |
| 64    | <i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub> | 210     | A                                | I                   | C <sub>12</sub> H <sub>13</sub> N <sub>6</sub> O                | 59.25   | 5.39 | 28.79 | 59.51   | 5.41 | 28.80 |
| 65    | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub> CH <sub>2</sub>               | 216     | E-D                              | I                   | C <sub>11</sub> H <sub>10</sub> ClN <sub>6</sub> O              | 50.10   | 8.32 | 26.56 | 50.02   | 3.88 | 26.67 |

<sup>a</sup> The sources for the 4,6-diamino-5-nitroso-2-(substituted) pyrimidines in which R<sub>1</sub> is H, *n*-C<sub>3</sub>H<sub>7</sub>, CH<sub>3</sub>S, C<sub>6</sub>H<sub>5</sub>, *p*-CH<sub>3</sub>OC<sub>6</sub>H<sub>4</sub>, *m*-ClC<sub>6</sub>H<sub>4</sub>, *p*-ClC<sub>6</sub>H<sub>4</sub>, and 2-thienyl were previously given in paper I of this series.<sup>3</sup> Other preparations: *m*-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>, J. Weinstock, U. S. Patent 2,963,478 (1960); *p*-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>, E. C. Taylor and T. S. Osdene, U. S. Patent, 2,975,180 (1961); CH<sub>3</sub>, E. C. Taylor, O. Vogl, and C. C. Cheng, *J. Am. Chem. Soc.*, **81**, 2442 (1959); *m*-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>, obtained from Arapahoe Chemicals, Inc. <sup>b</sup> See footnote a of Table I. <sup>c</sup> See Experimental Section. <sup>d</sup> See ref 10.

bamoyl nitrogen disubstituted. At the doses indicated compounds **184-186** were only mildly active and all other compounds were inactive. It is interesting to note that further substitution on the carbamoyl nitrogen bearing the active 2-diethylaminoethyl moiety (**180, 182**) eliminated the diuretic response.

In summary, the diuretic profiles of several 4,7-diamino-2-substituted N-substituted 6-pteridinecarboxamides, as determined in male Sprague-Dawley rats, show that activity is related to specific structural requirements. The more active compounds are those in which the 2 position of the pteridine nucleus bears an aromatic group, preferably phenyl or *m*-chlorophenyl, and in which the carbamoyl nitrogen bears a 2-dialkylaminoethyl or 2-(N-heterocyclic amino)ethyl group such as 2-diethylaminoethyl or 2-morpholinoethyl.

### Experimental Section<sup>8</sup>

The examples given below illustrate procedures used for the preparation of the compounds given in Tables I-V.

The 4,6-diamino-5-nitrosopyrimidines given in Table III were prepared in general by the reaction of a suitably substituted amidine hydrochloride with the silver salt of isonitrosomalonnitrile (method I) or by the direct nitrosation of the 4,6-diaminopyrimidine (method II). Illustrative examples follow.

**Method I.<sup>9</sup> 4,6-Diamino-2-trifluoromethyl-5-nitrosopyrimidine (59).**—To a solution of 24.5 g of trifluoroacetamide hydrochloride in 450 ml of absolute ethanol was added portionwise 33.6 g of finely powdered silver salt of isonitrosomalonnitrile. The reaction mixture was stirred for 2 hr and the AgCl was removed by filtration. The filtrate was evaporated to dryness *in vacuo* on a rotary evaporator to give the trifluoroacetamide salt of isonitrosomalonnitrile, mp 95-96°. The material thus obtained was dissolved in 150 ml of dimethylformamide (DMF) and boiled under reflux for 10 min. An excess of water was added, resulting in the deposition of a dark green powder. Recrystallization from aqueous DMF followed by recrystallization from aqueous acetic acid gave 13.5 g of the product, mp >360°.




(8) Melting points were determined on a Thomas-Hoover capillary melting point apparatus and are corrected. Yields reported in Tables I-V are the results of single experiments. Infrared spectra were determined in KBr disks on a Perkin-Elmer Model 21 spectrophotometer.

(9) Other 5-nitrosopyrimidine intermediates prepared by this method have been previously cited in ref 3.


TABLE IV  
 4,7-DIAMINO-N-SUBSTITUTED 6-PTERIDINECARBOXAMIDES

| Compd | R <sub>1</sub>  | R <sub>2</sub>  | Recrystn |                       | Formula | -% calcd-  |       |      | -% found- |       |      |       |
|-------|---|---|----------|-----------------------|---------|--|-------|------|-----------|-------|------|-------|
|       |   |   | Mp, °C   | sol-vent <sup>a</sup> |         | Yield, %   | C     | H    | N         | C     | H    | N     |
| 66    | H   | H   | >360     | G-D                   | 44      | C <sub>7</sub> H <sub>7</sub> N <sub>5</sub> O                           | 40.97 | 3.44 | 47.78     | 41.21 | 3.71 | 47.33 |
| 67    | H   | ( <i>i</i> -Pr) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>   | 303      | G-D                   | 62      | C <sub>14</sub> H <sub>24</sub> N <sub>8</sub> O                         | 54.20 | 7.28 | 33.71     | 54.22 | 6.88 | 33.97 |
| 68    | CH <sub>3</sub>   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                              | 250      | A                     | 70      | C <sub>15</sub> H <sub>24</sub> N <sub>8</sub> O                         | 54.20 | 7.28 | 33.71     | 53.49 | 7.65 | 33.80 |
| 69    | CF <sub>3</sub>   | H   | >360     | G-D                   | 73      | C <sub>8</sub> H <sub>5</sub> F <sub>3</sub> N <sub>7</sub> O            | 35.17 | 2.21 | 35.90     | 35.39 | 2.39 | 35.67 |
| 70    | CF <sub>3</sub>   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                              | 327      | A                     | 60      | C <sub>14</sub> H <sub>13</sub> F <sub>3</sub> N <sub>8</sub> O          | 40.16 | 5.14 | 30.10     | 44.88 | 5.01 | 29.88 |
| 71    | <i>n</i> -C <sub>3</sub> H <sub>7</sub>   | H   | >360     | G-D                   | 81      | C <sub>10</sub> H <sub>13</sub> N <sub>7</sub> O                         | 48.57 | 5.29 | 39.65     | 48.43 | 5.11 | 39.45 |
| 72    | <i>n</i> -C <sub>3</sub> H <sub>7</sub>   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                              | 266      | A-D                   | 96      | C <sub>16</sub> H <sub>26</sub> N <sub>8</sub> O · 0.5H <sub>2</sub> O   | 54.97 | 7.65 | 31.53     | 54.50 | 7.48 | 31.74 |
| 73    | <i>n</i> -C <sub>3</sub> H <sub>7</sub>   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>                              | 244      | A-D                   | 74      | C <sub>17</sub> H <sub>28</sub> N <sub>8</sub> O · 0.5H <sub>2</sub> O   | 55.26 | 7.91 | 30.75     | 55.35 | 8.04 | 31.04 |
| 74    | CH <sub>3</sub> S   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                              | 300      | E-D                   | 78      | C <sub>14</sub> H <sub>22</sub> N <sub>8</sub> OS                        | 47.98 | 6.33 | 31.98     | 47.48 | 6.59 | 31.80 |
| 75    | CH <sub>3</sub> S   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>                              | 305      | E                     | 55      | C <sub>15</sub> H <sub>24</sub> N <sub>8</sub> OS                        | 49.43 | 6.64 | 30.75     | 49.47 | 6.49 | 30.72 |
| 76    | CH <sub>3</sub> S   | C <sub>2</sub> H <sub>5</sub> O(CH <sub>2</sub> ) <sub>3</sub>  | 299      | E-D                   | 89      | C <sub>16</sub> H <sub>19</sub> N <sub>7</sub> O <sub>2</sub> S          | 46.28 | 5.68 | 29.06     | 46.30 | 5.22 | 28.89 |
| 77    | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> NH | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                              | 191      | A-B                   | 4       | C <sub>15</sub> H <sub>24</sub> N <sub>10</sub> O                        | 54.52 | 8.19 | 33.47     | 54.06 | 7.97 | 33.43 |
| 78    | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub> NH | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>                              | 119      | F                     | 54      | C <sub>20</sub> H <sub>28</sub> N <sub>10</sub> O · 11/2H <sub>2</sub> O | 54.28 | 8.68 | 30.15     | 54.39 | 8.25 | 29.83 |
| 79    | NH <sub>2</sub> <sup>b,d</sup>  | H   | >360     | D                     | 32      | C <sub>7</sub> H <sub>8</sub> N <sub>8</sub> O                           | 38.18 | 3.66 | 50.89     | 38.48 | 3.61 | 49.95 |
| 80    | NH <sub>2</sub> <sup>c</sup>  | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                              | 312      | G-D                   | 75      | C <sub>13</sub> H <sub>20</sub> N <sub>8</sub> O · 0.5H <sub>2</sub> O   | 47.55 | 6.75 | 38.39     | 47.82 | 7.02 | 38.49 |
| 81    | NH <sub>2</sub> <sup>d</sup>  | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                              | 317      | G-D                   | 73      | C <sub>13</sub> H <sub>20</sub> N <sub>8</sub> O                         | 50.43 | 6.95 | 37.81     | 50.01 | 7.23 | 37.94 |
| 82    | NH <sub>2</sub> <sup>d</sup>  | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>  | 284      | A                     | 14      | C <sub>12</sub> H <sub>16</sub> N <sub>8</sub> O · 0.5H <sub>2</sub> O   | 45.85 | 6.41 | 40.11     | 46.13 | 6.43 | 40.22 |
| 83    | NH <sub>2</sub> <sup>d</sup>  | 2-Morpholinoethyl   | 294      | G-D                   | 90      | C <sub>13</sub> H <sub>18</sub> N <sub>8</sub> O <sub>2</sub>            | 46.84 | 5.74 | 37.82     | 46.67 | 5.93 | 37.81 |
| 84    | NH <sub>2</sub> <sup>d</sup>  | (CH <sub>3</sub> ) <sub>2</sub> CHO(CH <sub>2</sub> ) <sub>3</sub>  | 287      | A                     | 20      | C <sub>14</sub> H <sub>20</sub> N <sub>8</sub> O <sub>2</sub>            | 48.74 | 6.29 | 34.98     | 48.43 | 6.67 | 34.39 |
| 85    | NH <sub>2</sub> <sup>d</sup>  | <i>o</i> -C <sub>3</sub> H <sub>7</sub>   | 336      | G-D                   | 71      | C <sub>14</sub> H <sub>20</sub> N <sub>8</sub> O                         | 53.15 | 6.37 | 35.42     | 53.59 | 6.12 | 35.19 |
| 86    | Morpholino <sup>d</sup>   | H   | >360     | G-D                   | 39      | C <sub>14</sub> H <sub>14</sub> N <sub>8</sub> O <sub>2</sub>            | 45.51 | 4.87 | 38.60     | 45.66 | 5.22 | 38.68 |
| 87    | Morpholino <sup>d</sup>   | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>  | 241      | A-D                   | 88      | C <sub>15</sub> H <sub>25</sub> N <sub>8</sub> O <sub>2</sub>            | 51.18 | 6.71 | 33.58     | 50.75 | 7.06 | 33.63 |
| 88    | C <sub>6</sub> H <sub>5</sub> <sup>c</sup>  | H   | >360     | G-D                   | 85      | C <sub>13</sub> H <sub>11</sub> N <sub>7</sub> O                         | 55.51 | 3.94 | 34.86     | 55.44 | 3.62 | 34.65 |
| 89    | C <sub>6</sub> H <sub>5</sub>   | CH <sub>3</sub>   | 352      | G-D                   | 96      | C <sub>14</sub> H <sub>17</sub> N <sub>7</sub> O                         | 56.94 | 4.44 | 33.20     | 56.94 | 4.53 | 32.60 |
| 90    | C <sub>6</sub> H <sub>5</sub>   | C <sub>2</sub> H <sub>5</sub>   | 346      | E-D                   | 99      | C <sub>15</sub> H <sub>15</sub> N <sub>7</sub> O                         | 58.24 | 4.89 | 31.70     | 58.23 | 5.06 | 31.80 |
| 91    | C <sub>6</sub> H <sub>5</sub>   | <i>o</i> -C <sub>3</sub> H <sub>7</sub>   | 342      | G-D                   | 65      | C <sub>16</sub> H <sub>15</sub> N <sub>7</sub> O                         | 59.80 | 4.71 | 30.51     | 60.07 | 4.53 | 30.64 |
| 92    | C <sub>6</sub> H <sub>5</sub>   | <i>o</i> -C <sub>3</sub> H <sub>7</sub>   | 344      | G-D                   | 94      | C <sub>17</sub> H <sub>19</sub> N <sub>7</sub> O                         | 61.87 | 5.48 | 28.06     | 61.90 | 5.49 | 28.19 |
| 93    | C <sub>6</sub> H <sub>5</sub>   | <i>o</i> -C <sub>6</sub> H <sub>11</sub>  | 350      | G-D                   | 92      | C <sub>19</sub> H <sub>21</sub> N <sub>7</sub> O                         | 62.79 | 5.82 | 26.98     | 62.25 | 5.79 | 26.98 |
| 94    | C <sub>6</sub> H <sub>5</sub>   | <i>o</i> -C <sub>7</sub> H <sub>13</sub>  | 350      | A-C                   | 95      | C <sub>20</sub> H <sub>23</sub> N <sub>7</sub> O                         | 63.64 | 6.14 | 25.98     | 63.47 | 6.27 | 26.18 |
| 95    | C <sub>6</sub> H <sub>5</sub>   | <i>o</i> -C <sub>8</sub> H <sub>17</sub>  | 332      | G-D                   | 94      | C <sub>21</sub> H <sub>25</sub> N <sub>7</sub> O                         | 64.43 | 6.44 | 25.05     | 64.37 | 6.25 | 24.73 |
| 96    | C <sub>6</sub> H <sub>5</sub>   | 4-Pyridylmethyl   | 330      | G-D                   | 89      | C <sub>16</sub> H <sub>16</sub> N <sub>8</sub> O                         | 61.28 | 4.33 | 30.09     | 60.99 | 4.16 | 30.04 |
| 97    | C <sub>6</sub> H <sub>5</sub> <sup>c</sup>  | H <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>   | 303      | G-D                   | 90      | C <sub>17</sub> H <sub>16</sub> N <sub>8</sub> O                         | 55.54 | 4.97 | 34.55     | 55.75 | 5.27 | 34.68 |
| 98    | C <sub>6</sub> H <sub>5</sub>   | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>  | 294      | E-D                   | 51      | C <sub>17</sub> H <sub>26</sub> N <sub>8</sub> O                         | 57.94 | 5.72 | 31.80     | 57.95 | 6.18 | 31.65 |
| 99    | C <sub>6</sub> H <sub>5</sub>   | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>  | 281      | A                     | 89      | C <sub>18</sub> H <sub>28</sub> N <sub>8</sub> O                         | 59.00 | 6.05 | 30.58     | 59.07 | 6.29 | 30.80 |
| 100   | C <sub>6</sub> H <sub>5</sub>   | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>4</sub>  | 273      | A                     | 70      | C <sub>19</sub> H <sub>34</sub> N <sub>8</sub> O                         | 59.98 | 6.36 | 29.46     | 60.17 | 6.40 | 29.37 |
| 101   | C <sub>6</sub> H <sub>5</sub>   | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>5</sub>  | 275      | A                     | 68      | C <sub>20</sub> H <sub>36</sub> N <sub>8</sub> O                         | 60.89 | 6.64 | 28.41     | 60.78 | 6.64 | 28.64 |
| 102   | C <sub>6</sub> H <sub>5</sub>   | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>6</sub>  | 279      | A                     | 61      | C <sub>21</sub> H <sub>38</sub> N <sub>8</sub> O                         | 61.74 | 6.91 | 27.43     | 62.00 | 6.62 | 27.29 |
| 103   | C <sub>6</sub> H <sub>5</sub>   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                              | 280      | A                     | 100     | C <sub>19</sub> H <sub>24</sub> N <sub>8</sub> O                         | 59.98 | 6.36 | 29.46     | 60.11 | 6.46 | 29.25 |
| 104   | C <sub>6</sub> H <sub>5</sub>   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>                              | 272      | A                     | 80      | C <sub>20</sub> H <sub>26</sub> N <sub>8</sub> O                         | 60.89 | 6.64 | 28.41     | 61.09 | 6.93 | 28.55 |
| 105   | C <sub>6</sub> H <sub>5</sub>   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>4</sub>                              | 279      | A                     | 94      | C <sub>21</sub> H <sub>28</sub> N <sub>8</sub> O                         | 61.74 | 6.91 | 27.43     | 61.95 | 6.65 | 27.43 |
| 106   | C <sub>6</sub> H <sub>5</sub>   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>5</sub>                              | 290      | A                     | 82      | C <sub>22</sub> H <sub>30</sub> N <sub>8</sub> O                         | 62.53 | 7.16 | 26.52     | 62.71 | 7.20 | 26.54 |
| 107   | C <sub>6</sub> H <sub>5</sub>   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>7</sub>                              | 289      | A-D                   | 58      | C <sub>23</sub> H <sub>34</sub> N <sub>8</sub> O                         | 63.97 | 7.61 | 24.87     | 63.71 | 7.41 | 25.10 |
| 108   | C <sub>6</sub> H <sub>5</sub>   | ( <i>n</i> -C <sub>4</sub> H <sub>9</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>                   | 260      | A                     | 87      | C <sub>21</sub> H <sub>34</sub> N <sub>8</sub> O                         | 63.97 | 7.61 | 24.87     | 63.17 | 7.58 | 24.63 |
| 109   | C <sub>6</sub> H <sub>5</sub>   | 2-(1-Pyrrolidinyl)-ethyl  | 297      | A-D                   | 96      | C <sub>19</sub> H <sub>22</sub> N <sub>8</sub> O                         | 60.30 | 5.86 | 29.61     | 60.18 | 6.08 | 29.50 |
| 110   | C <sub>6</sub> H <sub>5</sub>   | [(CH <sub>3</sub> ) <sub>2</sub> CH] <sub>2</sub> N-(CH <sub>2</sub> ) <sub>2</sub>                         | 283      | E                     | 94      | C <sub>21</sub> H <sub>28</sub> N <sub>8</sub> O                         | 61.74 | 6.91 | 27.43     | 61.78 | 7.27 | 26.98 |
| 111   | C <sub>6</sub> H <sub>5</sub>   | (CH <sub>3</sub> ) <sub>3</sub> N <sup>+</sup> (CH <sub>2</sub> ) <sub>3</sub> I <sup>-</sup>               | 303      | D                     | 98      | C <sub>19</sub> H <sub>25</sub> N <sub>8</sub> O                         | 44.89 | 4.96 | 22.04     | 45.26 | 5.03 | 22.19 |
| 112   | C <sub>6</sub> H <sub>5</sub> <sup>c</sup>  | (C <sub>2</sub> H <sub>5</sub> ) <sub>3</sub> N <sup>+</sup> (CH <sub>2</sub> ) <sub>3</sub> I <sup>-</sup> | 247      | D                     | 66      | C <sub>22</sub> H <sub>31</sub> N <sub>8</sub> O                         | 48.00 | 5.68 | 20.36     | 47.44 | 5.69 | 20.28 |
| 113   | C <sub>6</sub> H <sub>5</sub>   | (CH <sub>3</sub> ) <sub>2</sub> NCH(CH <sub>3</sub> )-CH <sub>2</sub>                                       | 286      | E-D                   | 75      | C <sub>18</sub> H <sub>22</sub> N <sub>8</sub> O                         | 59.00 | 6.05 | 30.58     | 58.91 | 6.10 | 30.70 |
| 114   | C <sub>6</sub> H <sub>5</sub>   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub> -CHCH <sub>3</sub>           | 268      | E-D                   | 58      | C <sub>22</sub> H <sub>30</sub> N <sub>8</sub> O                         | 62.53 | 7.16 | 26.52     | 62.60 | 7.06 | 26.49 |
| 115   | C <sub>6</sub> H <sub>5</sub>   | (HOCH <sub>2</sub> CH <sub>2</sub> ) <sub>2</sub> N-(CH <sub>2</sub> ) <sub>2</sub>                         | 230      | A-D                   | 75      | C <sub>17</sub> H <sub>17</sub> N <sub>8</sub> O <sub>2</sub>            | 55.33 | 5.86 | 27.07     | 55.36 | 5.80 | 27.03 |
| 116   | C <sub>6</sub> H <sub>5</sub>   | 2-Piperidinoethyl   | 284      | G-D                   | 83      | C <sub>20</sub> H <sub>25</sub> N <sub>8</sub> O                         | 61.20 | 6.16 | 28.55     | 61.08 | 5.90 | 28.62 |
| 117   | C <sub>6</sub> H <sub>5</sub>   | 3-Piperidinoethyl   | 271      | A                     | 67      | C <sub>21</sub> H <sub>26</sub> N <sub>8</sub> O                         | 62.05 | 6.45 | 27.57     | 62.21 | 6.40 | 27.32 |

TABLE IV (Continued)


| Compd | R <sub>1</sub>  | R <sub>2</sub>  | Recrystn |          |          | Formula   | % calcd |      |       | % found |      |       |
|-------|---|---|----------|----------|----------|---|---------|------|-------|---------|------|-------|
|       |   |   | Mp, °C   | sol-vent | Yield, % |   | C       | H    | N     | C       | H    | N     |
| 118   | C <sub>6</sub> H <sub>5</sub>   | 2-Morpholinoethyl   | 281      | E-D      | 73       | C <sub>19</sub> H <sub>22</sub> N <sub>8</sub> O <sub>2</sub>                 | 57.85   | 5.62 | 28.41 | 58.14   | 5.76 | 28.22 |
| 119   | C <sub>6</sub> H <sub>5</sub>   | 3-Morpholinopropyl  | 260      | A        | 78       | C <sub>20</sub> H <sub>24</sub> N <sub>8</sub> O <sub>2</sub>                 | 58.81   | 5.92 | 27.44 | 58.81   | 5.92 | 27.38 |
| 120   | C <sub>6</sub> H <sub>5</sub>   | HO(CH <sub>2</sub> ) <sub>2</sub>   | 324      | A        | 81       | C <sub>15</sub> H <sub>15</sub> N <sub>7</sub> O <sub>2</sub>                 | 55.37   | 4.65 | 30.14 | 55.80   | 4.44 | 29.77 |
| 121   | C <sub>6</sub> H <sub>5</sub>   | HOCH <sub>2</sub> CHC <sub>2</sub> H <sub>5</sub>                                   | 291      | G-D      | 86       | C <sub>17</sub> H <sub>19</sub> N <sub>7</sub> O <sub>2</sub>                 | 57.77   | 5.42 | 27.75 | 57.91   | 5.49 | 27.73 |
| 122   | C <sub>6</sub> H <sub>5</sub>   | (HOCH <sub>2</sub> ) <sub>2</sub> CCH <sub>3</sub>                                  | 295      | G-D      | 80       | C <sub>17</sub> H <sub>19</sub> N <sub>7</sub> O <sub>3</sub>                 | 55.29   | 5.19 | 26.54 | 55.00   | 5.07 | 26.38 |
| 123   | C <sub>6</sub> H <sub>5</sub>   | HO(CH <sub>2</sub> ) <sub>2</sub> O(CH <sub>2</sub> ) <sub>2</sub>                  | 242      | E        | 95       | C <sub>17</sub> H <sub>19</sub> N <sub>7</sub> O <sub>3</sub>                 | 55.28   | 5.19 | 26.54 | 54.99   | 5.35 | 26.44 |
| 124   | C <sub>6</sub> H <sub>5</sub>   | CH <sub>3</sub> O(CH <sub>2</sub> ) <sub>2</sub>                                    | 293      | E        | 76       | C <sub>16</sub> H <sub>17</sub> N <sub>7</sub> O <sub>2</sub>                 | 56.63   | 5.05 | 28.90 | 56.32   | 4.91 | 28.61 |
| 125   | C <sub>6</sub> H <sub>5</sub>   | CH <sub>3</sub> O(CH <sub>2</sub> ) <sub>3</sub>                                    | 285      | A        | 75       | C <sub>17</sub> H <sub>19</sub> N <sub>7</sub> O <sub>2</sub>                 | 57.78   | 5.42 | 27.75 | 58.07   | 5.62 | 27.49 |
| 126   | C <sub>6</sub> H <sub>5</sub>   | (CH <sub>3</sub> ) <sub>2</sub> CHO(CH <sub>2</sub> ) <sub>3</sub>                  | 265      | A-D      | 82       | C <sub>19</sub> H <sub>23</sub> N <sub>7</sub> O · 0.33H <sub>2</sub> O       | 61.44   | 6.42 | 26.40 | 61.50   | 6.74 | 26.08 |
| 127   | C <sub>6</sub> H <sub>5</sub>   | (C <sub>2</sub> H <sub>5</sub> O) <sub>2</sub> CHCH <sub>2</sub>                    | 235      | A        | 76       | C <sub>19</sub> H <sub>23</sub> N <sub>7</sub> O <sub>3</sub>                 | 57.42   | 5.83 | 24.67 | 57.42   | 5.70 | 24.43 |
| 128   | C <sub>6</sub> H <sub>5</sub>   | C <sub>2</sub> H <sub>5</sub> O(CH <sub>2</sub> ) <sub>2</sub>                      | 282      | A        | 69       | C <sub>17</sub> H <sub>19</sub> N <sub>7</sub> O <sub>2</sub>                 | 57.78   | 5.42 | 27.75 | 57.99   | 5.76 | 28.01 |
| 129   | C <sub>6</sub> H <sub>5</sub>   | C <sub>2</sub> H <sub>5</sub> O(CH <sub>2</sub> ) <sub>3</sub>                      | 279      | E-D      | 77       | C <sub>18</sub> H <sub>21</sub> N <sub>7</sub> O <sub>2</sub>                 | 58.84   | 5.76 | 26.69 | 59.15   | 5.77 | 26.41 |
| 130   | C <sub>6</sub> H <sub>5</sub>   |    | 303      | E-D      | 90       | C <sub>19</sub> H <sub>19</sub> N <sub>7</sub> O <sub>2</sub>                 | 60.47   | 5.08 | 25.98 | 60.64   | 5.11 | 25.83 |
| 131   | C <sub>6</sub> H <sub>5</sub>   | C <sub>2</sub> H <sub>5</sub> S(CH <sub>2</sub> ) <sub>2</sub>                      | 293      | E-D      | 77       | C <sub>17</sub> H <sub>19</sub> N <sub>7</sub> OS                             | 55.27   | 5.18 | 26.54 | 55.51   | 5.11 | 26.70 |
| 132   | C <sub>6</sub> H <sub>5</sub>   | C <sub>2</sub> H <sub>5</sub> O <sub>2</sub> CCH <sub>2</sub>                       | 300      | A        | 78       | C <sub>17</sub> H <sub>17</sub> N <sub>7</sub> O <sub>3</sub>                 | 55.58   | 4.66 | 26.69 | 55.88   | 4.74 | 26.53 |
| 133   | C <sub>6</sub> H <sub>5</sub>   | <i>p</i> -C <sub>2</sub> H <sub>5</sub> OCOC <sub>6</sub> H <sub>4</sub>            | 359      | G-D      | 76       | C <sub>22</sub> H <sub>19</sub> N <sub>7</sub> O <sub>3</sub>                 | 61.53   | 4.46 | 22.83 | 61.35   | 4.62 | 22.72 |
| 134   | <i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                    | 275      | A        | 84       | C <sub>18</sub> H <sub>22</sub> N <sub>8</sub> O                              | 59.00   | 6.05 | 30.38 | 58.98   | 6.06 | 30.28 |
| 135   | <i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 277      | A-D      | 92       | C <sub>20</sub> H <sub>26</sub> N <sub>8</sub> O                              | 60.89   | 6.64 | 28.41 | 61.14   | 6.72 | 28.28 |
| 136   | <i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>      | 287      | E-D      | 78       | C <sub>21</sub> H <sub>28</sub> N <sub>8</sub> O                              | 61.74   | 6.91 | 27.43 | 61.78   | 6.76 | 27.61 |
| 137   | <i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | 2-Morpholinoethyl   | 273      | E-D      | 82       | C <sub>20</sub> H <sub>24</sub> N <sub>8</sub> O <sub>2</sub>                 | 58.81   | 5.92 | 27.44 | 58.54   | 5.95 | 27.42 |
| 138   | <i>m</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 264      | A-D      | 68       | C <sub>20</sub> H <sub>26</sub> N <sub>8</sub> O                              | 60.89   | 6.64 | 28.41 | 60.73   | 6.52 | 28.38 |
| 139   | <i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | <i>c</i> -C <sub>6</sub> H <sub>11</sub>  | >360     | G-D      | 91       | C <sub>20</sub> H <sub>28</sub> N <sub>7</sub> O                              | 63.64   | 6.14 | 25.98 | 63.64   | 6.40 | 26.01 |
| 140   | <i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>                    | 302      | A-D      | 95       | C <sub>19</sub> H <sub>24</sub> N <sub>8</sub> O                              | 59.98   | 6.36 | 29.46 | 59.61   | 6.54 | 29.07 |
| 141   | <i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 284      | A-D      | 93       | C <sub>20</sub> H <sub>26</sub> N <sub>8</sub> O                              | 60.89   | 6.64 | 28.41 | 60.92   | 6.59 | 28.32 |
| 142   | <i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | (CH <sub>3</sub> ) <sub>2</sub> NCHCH <sub>3</sub> CH <sub>2</sub>                  | 300      | A-D      | 87       | C <sub>19</sub> H <sub>24</sub> N <sub>8</sub> O · 0.5H <sub>2</sub> O        | 58.59   | 6.47 | 28.78 | 58.78   | 6.40 | 29.21 |
| 143   | <i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | 2-Morpholinoethyl   | 309      | E-D      | 90       | C <sub>20</sub> H <sub>24</sub> N <sub>8</sub> O <sub>2</sub>                 | 58.67   | 5.93 | 27.59 | 58.81   | 5.92 | 27.44 |
| 144   | <i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | (C <sub>2</sub> H <sub>5</sub> O) <sub>2</sub> CHCH <sub>2</sub>                    | 249      | A        | 67       | C <sub>20</sub> H <sub>25</sub> N <sub>7</sub> O <sub>2</sub>                 | 58.37   | 6.12 | 23.83 | 58.34   | 5.97 | 24.02 |
| 145   | <i>m</i> -CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 293      | A        | 53       | C <sub>20</sub> H <sub>23</sub> F <sub>3</sub> N <sub>8</sub> O               | 53.56   | 5.17 | 24.99 | 53.39   | 5.19 | 25.01 |
| 146   | <i>m</i> -CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub>                 | HO(CH <sub>2</sub> ) <sub>2</sub> O(CH <sub>2</sub> ) <sub>2</sub>                  | 228      | A-D      | 57       | C <sub>18</sub> H <sub>18</sub> F <sub>3</sub> N <sub>7</sub> O <sub>3</sub>  | 49.43   | 4.15 | 22.42 | 49.29   | 4.23 | 22.16 |
| 147   | <i>p</i> -CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>                | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                    | 297      | A        | 58       | C <sub>18</sub> H <sub>22</sub> N <sub>8</sub> O <sub>2</sub>                 | 56.53   | 5.80 | 29.30 | 55.87   | 5.61 | 29.03 |
| 148   | <i>p</i> -CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>                | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 283      | E-D      | 79       | C <sub>20</sub> H <sub>26</sub> N <sub>8</sub> O · 0.5H <sub>2</sub> O        | 57.26   | 6.49 | 26.72 | 57.12   | 6.44 | 27.25 |
| 149   | <i>p</i> -CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>                | 2-Morpholinoethyl   | 313      | E-D      | 26       | C <sub>20</sub> H <sub>24</sub> N <sub>8</sub> O <sub>3</sub>                 | 56.59   | 5.70 | 26.40 | 56.67   | 5.67 | 26.24 |
| 150   | <i>m</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                    | 302      | E-D      | 53       | C <sub>17</sub> H <sub>19</sub> ClN <sub>8</sub> O                            | 52.78   | 4.95 | 28.97 | 52.98   | 4.71 | 28.91 |
| 151   | <i>m</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>                    | 280      | H        | 87       | C <sub>18</sub> H <sub>21</sub> ClN <sub>8</sub> O                            | 53.93   | 5.28 | 27.95 | 53.77   | 5.03 | 27.92 |
| 152   | <i>m</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>4</sub>                    | 285      | H        | 60       | C <sub>19</sub> H <sub>23</sub> ClN <sub>8</sub> O                            | 55.00   | 5.59 | 27.01 | 55.27   | 5.86 | 27.23 |
| 153   | <i>m</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>5</sub>                    | 277      | A-D      | 55       | C <sub>20</sub> H <sub>25</sub> ClN <sub>8</sub> O                            | 56.00   | 5.88 | 26.13 | 56.12   | 6.31 | 26.21 |
| 154   | <i>m</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>6</sub>                    | 277      | H        | 37       | C <sub>21</sub> H <sub>27</sub> ClN <sub>8</sub> O                            | 56.94   | 6.14 | 25.30 | 57.11   | 6.48 | 25.24 |
| 155   | <i>m</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 275      | A        | 40       | C <sub>19</sub> H <sub>23</sub> ClN <sub>8</sub> O                            | 55.00   | 5.59 | 27.01 | 54.72   | 5.35 | 26.89 |
| 156   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>                    | 329      | I        | 65       | C <sub>17</sub> H <sub>19</sub> ClN <sub>8</sub> O                            | 52.78   | 4.95 | 28.97 | 52.64   | 5.17 | 28.52 |
| 157   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>4</sub>                    | 321      | I        | 54       | C <sub>19</sub> H <sub>23</sub> ClN <sub>8</sub> O                            | 55.00   | 5.59 | 27.01 | 54.72   | 5.55 | 26.39 |
| 158   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 309      | E-D      | 71       | C <sub>19</sub> H <sub>23</sub> ClN <sub>8</sub> O                            | 52.71   | 5.82 | 25.89 | 52.53   | 5.95 | 25.94 |
| 159   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub>      | 306      | A-D      | 81       | C <sub>20</sub> H <sub>25</sub> ClN <sub>8</sub> O                            | 56.00   | 5.88 | 26.13 | 56.02   | 6.29 | 26.00 |
| 160   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub>                               | 2-Morpholinoethyl   | 318      | A-D      | 86       | C <sub>19</sub> H <sub>21</sub> ClN <sub>8</sub> O <sub>2</sub>               | 53.21   | 4.93 | 26.13 | 52.97   | 4.93 | 26.34 |
| 161   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub>                               | C <sub>2</sub> H <sub>5</sub> O(CH <sub>2</sub> ) <sub>2</sub>                      | 303      | A-D      | 86       | C <sub>17</sub> H <sub>18</sub> ClN <sub>7</sub> O <sub>2</sub>               | 52.65   | 4.68 | 25.28 | 52.78   | 4.38 | 25.46 |
| 162   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub>                               | C <sub>2</sub> H <sub>5</sub> O(CH <sub>2</sub> ) <sub>3</sub>                      | 279      | E-D      | 77       | C <sub>18</sub> H <sub>21</sub> N <sub>7</sub> O <sub>2</sub>                 | 58.84   | 5.76 | 26.69 | 59.15   | 5.77 | 26.41 |
| 163   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub>                               |  | 327      | E-D      | 49       | C <sub>19</sub> H <sub>18</sub> ClN <sub>7</sub> O <sub>2</sub>               | 55.41   | 4.41 | 23.81 | 55.12   | 4.18 | 23.66 |
| 164   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub>                               | (C <sub>2</sub> H <sub>5</sub> O) <sub>2</sub> CHCH <sub>2</sub>                    | 248      | A        | 75       | C <sub>19</sub> H <sub>22</sub> ClN <sub>7</sub> O <sub>3</sub>               | 52.84   | 5.14 | 22.70 | 52.87   | 5.30 | 22.47 |
| 165   | 3,4-Cl <sub>2</sub> C <sub>6</sub> H <sub>3</sub>                       | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 304      | A        | 77       | C <sub>19</sub> H <sub>22</sub> Cl <sub>2</sub> N <sub>8</sub> O              | 50.78   | 4.94 | 24.94 | 50.11   | 5.19 | 24.96 |
| 166   | 3,4-Cl <sub>2</sub> C <sub>6</sub> H <sub>3</sub>                       | C <sub>2</sub> H <sub>5</sub> O(CH <sub>2</sub> ) <sub>2</sub>                      | 285      | A        | 79       | C <sub>17</sub> H <sub>17</sub> Cl <sub>2</sub> N <sub>7</sub> O <sub>2</sub> | 48.35   | 4.06 | 23.22 | 48.58   | 3.97 | 23.33 |
| 167   | 2-Thienyl   | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 273      | A        | 77       | C <sub>17</sub> H <sub>22</sub> N <sub>8</sub> OS                             | 52.83   | 5.74 | 29.00 | 52.98   | 5.50 | 28.98 |
| 168   | 2-Thienyl   | 2-Morpholinoethyl   | 274      | E-D      | 62       | C <sub>17</sub> H <sub>20</sub> N <sub>8</sub> O <sub>2</sub> S               | 50.98   | 5.03 | 27.98 | 51.56   | 5.03 | 28.07 |
| 169   | 2-Thienyl   | <i>c</i> -C <sub>6</sub> H <sub>11</sub> NH(CH <sub>2</sub> ) <sub>3</sub>          | 240      | E-D      | 70       | C <sub>20</sub> H <sub>26</sub> N <sub>8</sub> OS                             | 56.32   | 6.14 | 26.27 | 56.05   | 6.04 | 25.95 |
| 170   | 2-Thienyl   |  | 305      | E-D      | 52       | C <sub>17</sub> H <sub>17</sub> N <sub>7</sub> O <sub>2</sub> S               | 53.25   | 4.45 | 25.57 | 53.47   | 4.63 | 25.41 |
| 171   | <i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub> | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 262      | A        | 73       | C <sub>21</sub> H <sub>28</sub> N <sub>8</sub> O                              | 61.74   | 6.91 | 27.43 | 61.65   | 7.00 | 26.93 |
| 172   | <i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub> | C <sub>2</sub> H <sub>5</sub> O(CH <sub>2</sub> ) <sub>2</sub>                      | 290      | E-D      | 61       | C <sub>19</sub> H <sub>23</sub> N <sub>7</sub> O <sub>2</sub>                 | 59.83   | 6.08 | 25.71 | 60.10   | 6.19 | 25.64 |
| 173   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub> CH <sub>2</sub>               | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub>      | 280      | G        | 33       | C <sub>20</sub> H <sub>25</sub> ClN <sub>8</sub> O                            | 56.00   | 5.88 | 26.13 | 55.85   | 5.80 | 25.81 |
| 174   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub> CH <sub>2</sub>               | C <sub>2</sub> H <sub>5</sub> O(CH <sub>2</sub> ) <sub>2</sub>                      | 311      | G        | 80       | C <sub>19</sub> H <sub>20</sub> ClN <sub>7</sub> O <sub>2</sub>               | 53.80   | 5.02 | 24.40 | 53.88   | 5.12 | 24.28 |

<sup>a</sup> See footnote *a* of Table I. <sup>b</sup> See ref 4b of text. <sup>c</sup> Prepared from **75** and 3-diethylaminopropylamine by procedure used for the preparation of **77**. <sup>d</sup> Prepared in 2-ethoxyethanol. <sup>e</sup> I. J. Pachter and P. E. Nemeth, *J. Org. Chem.*, **28**, 1187 (1963). <sup>f</sup> Prepared from 4,5-diamino-5-nitroso-2-phenylpyrimidine and **22** in ethanol using 1.2 equiv of NaOEt. <sup>g</sup> Prepared from **104** and ethyl iodide in refluxing ethanol.

TABLE V  
 4,6-DIAMINO-N,N-DISUBSTITUTED 6-PTERIDINECARBOXAMIDES


| Compd | R <sub>1</sub>  | R <sub>2</sub>   | Mp, °C           | Recrystall solvent <sup>a</sup> | Yield, % | Formula   | Calcd |      |       | Found |      |       |
|-------|---|--|------------------|---------------------------------|----------|---|-------|------|-------|-------|------|-------|
|       |   |  |                  |                                 |          |   | C     | H    | N     | C     | H    | N     |
| 175   | NH <sub>2</sub> <sup>b</sup>                            | Piperidino   | 305              | D-E                             | 16       | C <sub>12</sub> H <sub>16</sub> N <sub>8</sub> O                        | 49.99 | 5.59 | 38.87 | 49.73 | 6.01 | 38.67 |
| 176   | NH <sub>2</sub> <sup>b</sup>                            | 1-Hexahydroazepinyl  | 305              | E                               | 71       | C <sub>13</sub> H <sub>18</sub> N <sub>8</sub> O · 0.33H <sub>2</sub> O | 50.64 | 6.10 | 36.35 | 51.08 | 6.32 | 36.43 |
| 177   | C <sub>6</sub> H <sub>5</sub>                           | (CH <sub>2</sub> ) <sub>2</sub> N  | 320 <sup>c</sup> | G-D                             | 94       | C <sub>15</sub> H <sub>15</sub> N <sub>7</sub> O                        | 58.24 | 4.89 | 31.70 | 58.34 | 5.06 | 30.94 |
| 178   | C <sub>6</sub> H <sub>5</sub>                           | <i>o</i> -C <sub>6</sub> H <sub>4</sub> NCH <sub>3</sub>   | 327              | G-D                             | 94       | C <sub>20</sub> H <sub>23</sub> N <sub>7</sub> O                        | 63.64 | 6.14 | 25.98 | 63.63 | 5.91 | 26.06 |
| 179   | C <sub>6</sub> H <sub>5</sub>                           | (CH <sub>2</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> NCH <sub>3</sub>  | 234              | A                               | 90       | C <sub>18</sub> H <sub>22</sub> N <sub>8</sub> O                        | 59.00 | 6.05 | 30.58 | 58.70 | 6.28 | 30.04 |
| 180   | C <sub>6</sub> H <sub>5</sub>                           | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> NCH <sub>3</sub>  | 206              | A                               | 76       | C <sub>20</sub> H <sub>26</sub> N <sub>8</sub> O                        | 60.89 | 6.64 | 28.41 | 60.83 | 6.59 | 28.11 |
| 181   | C <sub>6</sub> H <sub>5</sub>                           | (CH <sub>2</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> NC <sub>2</sub> H <sub>5</sub>  | 218              | A-D                             | 86       | C <sub>19</sub> H <sub>24</sub> N <sub>8</sub> O                        | 59.98 | 6.36 | 29.46 | 59.33 | 6.29 | 29.27 |
| 182   | C <sub>6</sub> H <sub>5</sub>                           | (C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> NC <sub>2</sub> H <sub>5</sub>                          | 188              | A                               | 24       | C <sub>21</sub> H <sub>28</sub> N <sub>8</sub> O                        | 61.74 | 6.91 | 27.43 | 61.97 | 7.02 | 27.63 |
| 183   | C <sub>6</sub> H <sub>5</sub>                           | ( <i>i</i> -C <sub>3</sub> H <sub>7</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> N( <i>i</i> -C <sub>3</sub> H <sub>7</sub> ) | 252              | A-D                             | 33       | C <sub>24</sub> H <sub>34</sub> N <sub>8</sub> O                        | 63.97 | 7.61 | 24.87 | 64.10 | 7.32 | 24.94 |
| 184   | C <sub>6</sub> H <sub>5</sub>                           | 1-Pyrrolidinyl   | 340              | G-D                             | 53       | C <sub>17</sub> H <sub>17</sub> N <sub>7</sub> O                        | 60.88 | 5.11 | 29.24 | 60.94 | 5.52 | 29.03 |
| 185   | C <sub>6</sub> H <sub>5</sub>                           | Piperidino   | 273 <sup>c</sup> | A-D                             | 71       | C <sub>18</sub> H <sub>19</sub> N <sub>7</sub> O                        | 61.87 | 5.49 | 28.06 | 62.02 | 5.76 | 27.84 |
| 186   | C <sub>6</sub> H <sub>5</sub>                           | 1-Hexahydroazepinyl  | 266              | A                               | 84       | C <sub>19</sub> H <sub>21</sub> N <sub>7</sub> O                        | 62.79 | 5.82 | 26.98 | 62.96 | 5.94 | 26.82 |
| 187   | C <sub>6</sub> H <sub>5</sub>                           | Morpholino   | 327              | G-D                             | 91       | C <sub>17</sub> H <sub>17</sub> N <sub>7</sub> O <sub>2</sub>           | 58.11 | 4.88 | 27.91 | 58.34 | 4.93 | 27.83 |
| 188   | C <sub>6</sub> H <sub>5</sub>                           | Thiomorpholino   | 314              | F-C                             | 36       | C <sub>17</sub> H <sub>17</sub> N <sub>7</sub> OS                       | 55.57 | 4.66 | 26.69 | 55.42 | 4.61 | 26.46 |
| 189   | C <sub>6</sub> H <sub>5</sub>                           | 4-Methyl-1-piperazinyl   | 271              | A-D                             | 83       | C <sub>18</sub> H <sub>20</sub> N <sub>8</sub> O                        | 59.33 | 5.53 | 30.75 | 59.01 | 5.58 | 30.62 |
| 190   | C <sub>6</sub> H <sub>5</sub>                           | 4-(2-Hydroxyethyl)-1-piperazinyl   | 279              | G-D                             | 96       | C <sub>19</sub> H <sub>22</sub> N <sub>8</sub> O <sub>2</sub>           | 57.85 | 5.62 | 28.41 | 58.08 | 5.64 | 28.38 |
| 191   | <i>p</i> -ClC <sub>6</sub> H <sub>4</sub>               | 4-(2-Hydroxyethyl)-1-piperazinyl   | 292              | G-D                             | 89       | C <sub>19</sub> H <sub>21</sub> ClN <sub>8</sub> O <sub>2</sub>         | 53.21 | 4.93 | 26.13 | 53.28 | 4.77 | 26.06 |
| 192   | <i>o</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub> | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> NCH <sub>3</sub>  | 216              | A                               | 75       | C <sub>19</sub> N <sub>2</sub> N <sub>8</sub> O                         | 59.98 | 6.36 | 29.46 | 60.27 | 6.46 | 29.42 |
| 193   | <i>p</i> -CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub> | Morpholino   | 338              | G-D                             | 91       | C <sub>18</sub> H <sub>19</sub> N <sub>7</sub> O <sub>2</sub>           | 59.15 | 5.29 | 26.84 | 59.06 | 5.36 | 26.78 |
| 194   | Morpholino <sup>b</sup>                                 | (CH <sub>3</sub> ) <sub>2</sub> N(CH <sub>2</sub> ) <sub>2</sub> NCH <sub>3</sub>  | 245              | E                               | 35       | C <sub>18</sub> H <sub>20</sub> N <sub>8</sub> O <sub>2</sub>           | 51.18 | 6.71 | 33.58 | 51.08 | 6.67 | 33.52 |
| 195   | Morpholino <sup>b</sup>                                 | Morpholino   | 334              | F-C                             | 19       | C <sub>18</sub> H <sub>20</sub> N <sub>8</sub> O <sub>3</sub>           | 49.99 | 5.59 | 31.10 | 50.22 | 5.73 | 30.72 |

<sup>a</sup> See footnote *a* of Table I. <sup>b</sup> Prepared in 2-ethoxyethanol. <sup>c</sup> Melted with decomposition.


 TABLE VI  
 EFFECT ON DIURETIC ACTIVITY OF VARYING THE SUBSTITUENTS ON THE CARBAMOYL GROUP


| Compd | R <sub>2</sub>   | Dose, mg/kg, and route | T/U <sup>a</sup> |      |      |
|-------|--|------------------------|------------------|------|------|
|       |  |                        | Vol              | Na   | Na/K |
| 88    | H  | 25 <i>po</i>           | 1.34             | 1.38 | 5.91 |
| 90    | C <sub>2</sub> H <sub>5</sub>  | 25 <i>po</i>           | 1.28             | 1.25 | 5.19 |
| 118   | 2-Morpholinoethyl  | 25 <i>po</i>           | 1.71             | 2.06 | 5.52 |
| 116   | 2-Piperidinoethyl  | 25 <i>po</i>           | 1.46             | 1.45 | 5.73 |
| 109   | 2-(1-Pyrrolidinyl)ethyl  | 25 <i>po</i>           | 1.08             | 1.31 | 3.60 |
| 103   | (CH <sub>2</sub> ) <sub>2</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> | 25 <i>po</i>           | 1.59             | 1.66 | 5.91 |
| 128   | (CH <sub>2</sub> ) <sub>2</sub> OC <sub>2</sub> H <sub>5</sub>                 | 25 <i>po</i>           | 1.23             | 1.33 | 4.82 |
| 127   | CH <sub>2</sub> CH(OC <sub>2</sub> H <sub>5</sub> ) <sub>2</sub>               | 25 <i>po</i>           | 1.10             | 1.10 | 5.07 |
| 130   |  | 12 <i>po</i>           | 0.77             | 0.89 | 3.59 |
| 132   | CH <sub>2</sub> CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub>                  | 25 <i>po</i>           | 1.16             | 1.27 | 4.60 |
| 133   | <i>p</i> -C <sub>6</sub> H <sub>4</sub> OCOC <sub>2</sub> H <sub>5</sub>       | 25 <i>po</i>           | 0.85             | 0.91 | 3.93 |
| 131   | CH <sub>2</sub> CH <sub>2</sub> SC <sub>2</sub> H <sub>5</sub>                 | 25 <i>ip</i>           | 0.72             | 0.88 | 3.61 |
| 96    | 4-Pyridylmethyl  | 25 <i>po</i>           | 1.46             | 1.40 | 4.86 |

<sup>a</sup> Average ratios of urine and sodium levels in test (T) animals to those of urea-dosed (U) animals. All ratios greater than unity represent statistically significant responses.

**Method II. 4,6-Diamino-2-morpholino-5-nitrosopyrimidine (60).**<sup>10</sup>—4,6-Diamino-2-morpholinopyrimidine (39 g) was dissolved in a mixture of 12 g of glacial acetic acid and 250 ml of

(10) R. M. Cresswell and T. Strauss, *J. Org. Chem.*, **28**, 2563 (1963), prepared **60** by the reaction of 4,6-diamino-2-methylthio-5-nitrosopyrimidine with morpholine and reported mp 237–238° dec.

 TABLE VII  
 EFFECT ON DIURETIC ACTIVITY OF VARYING THE SUBSTITUENTS AT THE 2 POSITION


| Compd | R <sub>1</sub>                          | Dose, mg/kg, and route | T/U <sup>a</sup> |      |      |
|-------|---|------------------------|------------------|------|------|
|       |   |                        | Vol              | Na   | Na/K |
| 72    | <i>n</i> -C <sub>3</sub> H <sub>7</sub> | 25 <i>po</i>           | 0.77             | 0.87 | 3.61 |
| 74    | CH <sub>3</sub> S                       | 25 <i>ip</i>           | 0.64             | 0.63 | 2.64 |
| 80    | NH <sub>2</sub>                         | 25 <i>po</i>           | 0.93             | 0.89 | 3.34 |
| 103   | C <sub>6</sub> H <sub>5</sub>           | 25 <i>po</i>           | 1.59             | 1.66 | 5.91 |
| 167   | 2-Thiocytyl                             | 25 <i>po</i>           | 0.64             | 0.84 | 3.68 |


<sup>a</sup> See footnote *a*, Table VI.

water. To this solution was added dropwise, with stirring and cooling, a solution of 14 g of NaNO<sub>2</sub> in 100 ml of water. Acetic acid (12 g) was added. The red nitrosopyrimidine crystallized out of the solution after a few minutes. After 30 min the material amounted to 53 g, mp 235–236° dec. Recrystallization from ethanol gave the analytical sample, mp 236° dec.

**2-Cyano-N-(2-diethylaminoethyl)acetamide (29).**—A solution of 65.6 g of ethyl cyanoacetate and 58 g of 2-diethylaminoethylamine in 100 ml of absolute ethanol was boiled under reflux for 3 hr. The solvent was removed on a rotary evaporator *in vacuo* and the residual oil was distilled through a Vigreux column. The fraction distilling at 132° (0.3 mm) amounted to 60 g (66%); λ<sub>max</sub><sup>film</sup> 4.45 (C≡N), 5.99 (C=O), 6.46 μ (amide II).

**The Maleate Salt of 2-Cyano-N-(2-aminoethyl)acetamide (22).**—To 48 g of ethylenediamine was added dropwise and with stirring 22.6 g of ethyl cyanoacetate over the course of 50 min. The reaction mixture was allowed to stand for 2 days and concentrated *in vacuo* to small bulk on a rotary evaporator. To the residue was added 80 ml of ethanol and 25 g of maleic acid.


TABLE VIII  
EFFECT ON DIURETIC ACTIVITY OF VARYING THE SUBSTITUENT ON  
THE 2-PHENYL GROUP



| Compd | R                           | Dose,<br>mg/kg,<br>and<br>route | T/U <sup>a</sup> |      | Na/K |
|-------|-----------------------------|---------------------------------|------------------|------|------|
|       |                             |                                 | Vol              | Na   |      |
| 103   | H                           | 25 <i>po</i>                    | 1.59             | 1.66 | 5.91 |
| 135   | <i>o</i> -CH <sub>3</sub>   | 25 <i>po</i>                    | 1.22             | 1.30 | 3.77 |
| 138   | <i>m</i> -CH <sub>3</sub>   | 12 <i>po</i>                    | 1.29             | 1.35 | 5.22 |
| 141   | <i>p</i> -CH <sub>3</sub>   | 25 <i>po</i>                    | 1.42             | 1.32 | 4.93 |
| 145   | <i>m</i> -CF <sub>3</sub>   | 25 <i>ip</i>                    | 0.33             | 0.36 | 2.77 |
| 148   | <i>p</i> -CH <sub>3</sub> O | 25 <i>po</i>                    | 0.72             | 0.80 | 2.75 |
| 155   | <i>m</i> -Cl                | 25 <i>po</i>                    | 1.57             | 1.85 | 7.36 |
| 158   | <i>p</i> -Cl                | 25 <i>po</i>                    | 0.96             | 1.03 | 2.81 |
| 165   | 3,4-Cl <sub>2</sub>         | 25 <i>po</i>                    | 0.71             | 0.82 | 3.31 |

<sup>a</sup> See footnote a, Table VI.

TABLE IX  
EFFECT ON DIURETIC ACTIVITY OF INCREASING THE LENGTH OF  
THE METHYLENE CHAIN ATTACHED TO THE CARBAMOYL NITROGEN




| Compd | n | Dose,<br>mg/kg, and<br>route | T/U <sup>a</sup> |      | Na/K |
|-------|---|------------------------------|------------------|------|------|
|       |   |                              | Vol              | Na   |      |
| 103   | 2 | 25 <i>po</i>                 | 1.59             | 1.66 | 5.91 |
| 104   | 3 | 25 <i>po</i>                 | 1.43             | 1.13 | 5.24 |
| 105   | 4 | 25 <i>ip</i>                 | 0.76             | 0.96 | 3.18 |
| 106   | 5 | 25 <i>po</i>                 | 0.69             | 0.79 | 3.24 |

<sup>a</sup> See footnote a, Table VI.

After the heat of reaction subsided, the reaction vessel was cooled in ice to afford 49 g of a crystalline product, mp 155–160°. The infrared spectrum of this material indicated it to be the maleate salt of ethylenediamine. On further cooling of the filtrate the desired product (**22**) was obtained. Recrystallization from ethanol afforded 29 g of pure product:  $\lambda_{\text{max}}^{\text{KBr}}$  4.45 (C≡N), 3.05  $\mu$  (NH stretch).

In preparing the pteridinecarboxamides given in Tables IV and V a catalytic amount of sodium (0.01 g-atom) in 500 ml of refluxing ethanol was used, followed by the addition of 0.03 mole of a suitably substituted diamino-nitrosopyrimidine (Table III) and 0.032 mole of a cyanoacetamide (Tables I and II). A striking change in the color of the reaction solution from blue or

TABLE X  
EFFECT ON DIURETIC ACTIVITY OF N,N-DISUBSTITUTION ON  
THE CARBAMOYL NITROGEN



| Compd | R <sub>3</sub>   | Dose,<br>mg/kg<br><i>po</i> | T/U <sup>a</sup> |      | Na/K |
|-------|--|-----------------------------|------------------|------|------|
|       |  |                             | Vol              | Na   |      |
| 184   | 1-Pyrrolidinyl   | 25                          | 1.08             | 1.12 | 4.59 |
| 185   | Piperidino   | 25                          | 0.92             | 1.06 | 2.91 |
| 186   | 1-Hexahydroazepinyl  | 25                          | 0.95             | 1.01 | 4.60 |
| 187   | Morpholino   | 25                          | 0.97             | 0.98 | 5.06 |
| 180   | N(CH <sub>3</sub> )(CH <sub>2</sub> ) <sub>2</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub>                | 25                          | 0.76             | 0.86 | 4.37 |
| 182   | N(C <sub>2</sub> H <sub>5</sub> )(CH <sub>2</sub> ) <sub>2</sub> N-(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> | 25                          | 0.72             | 0.87 | 3.52 |

<sup>a</sup> See footnote a, Table VI.

green (nitroso compound) to yellow-brown (pteridine) generally occurred within a few minutes and marked the completion of the reaction. The method is illustrated by example **103**. In a number of examples where the 2 substituent of the diamino-nitrosopyrimidine was an amino function the reaction was carried out in boiling 2-ethoxyethanol.

**4,7-Diamino-N-(2-diethylaminoethyl)-2-phenyl-6-pteridine-carboxamide (103)**.—To a stirred solution of 0.2 g of sodium in 500 ml of absolute ethanol was added 6.5 g of 4,6-diamino-5-nitroso-2-phenylpyrimidine. The mixture was heated to boiling and 6 g of **29** was added. The mixture was allowed to reflux an additional 10 min and was then cooled and concentrated *in vacuo* on a rotary evaporator, yielding 11.4 g (100%) of product, mp 279–281°. Recrystallization from ethanol (300 ml) afforded 9.7 g of pure product: mp 280°;  $\lambda_{\text{max}}^{\text{KBr}}$  3.01, 3.15 (sh) (NH stretch), 6.04 (C=O), 6.18 (aromatic + NH deformation), 6.48  $\mu$  (aromatic + amide II).

**4,7-Diamino-N-(2-diethylaminoethyl)-2-(2-diethylaminoethyl-amino)-6-pteridinecarboxamide (77)**.—A solution of 2 g of 4,7-diamino-N-(2-diethylaminoethylamino)-2-methylthio-6-pteridine-carboxamide (**74**) in 10 ml of 2-diethylaminoethylamine was boiled under reflux for 24 hr. The excess amine was removed *in vacuo* on a rotary evaporator. Recrystallization of the residue from ethanol-ethyl acetate gave 0.1 g of product (**77**), mp 191°,  $\lambda_{\text{max}}^{\text{KBr}}$  6.04  $\mu$  (C=O).

**[3-(4,7-Diamino-2-phenyl-6-pteridinecarboxamido)propyl]trimethylammonium Iodide Salt (111)**.—To a solution of 2 g of 4,7-diamino-N-(3-dimethylaminopropyl)-2-phenyl-6-pteridine-carboxamide (**99**) in 50 ml of ethanol was added 1.4 g of methyl iodide. The reaction mixture was heated under reflux with stirring for 15 min and cooled in ice. The precipitate which was deposited amounted to 2.8 g. Recrystallization from boiling water gave the product, mp 303°.

**Acknowledgments.**—The authors are indebted to Mr. Ronald Stewart for technical assistance and to Dr. Gordon Ellis for the microanalyses.